Breast Cancer Research and Treatment

, Volume 121, Issue 1, pp 91–100 | Cite as

Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study

  • Jeanne Debess
  • Jens Østergaard Riis
  • Malene Cramer Engebjerg
  • Marianne Ewertz
Clinical trial


The purpose of this study was to examine cognitive function in patients with early breast cancer before and after adjuvant chemotherapy or 6 months of tamoxifen. We performed a population-based study in the county of North Jutland, Denmark, including 120 women aged <60 years who received adjuvant chemotherapy with seven cycles of cyclophosphamide, epirubicin and fluoruracil or adjuvant tamoxifen for 6 months for early breast cancer from 2004 to 2006. They were compared with an aged-matched group of 208 women without previous cancer selected randomly from the same population. Data were collected before start of adjuvant treatment and after 6 months by neuropsychological tests and questionnaires to evaluate cognitive function, quality of life and psychological distress. Neuropsychological tests did not reveal any differences in cognitive function between breast cancer patients after chemotherapy and healthy controls. Patients rated their own cognitive functions as improved after 6 months, and patients, who did not receive adjuvant medical treatment, reached the same level as controls within 6 months. Patients receiving chemotherapy or tamoxifen were up to three times more likely than controls to rate themselves as impaired at 6 months. Our results do not support that adjuvant chemotherapy is associated with cognitive side effects in breast cancer patients.


Breast cancer Cognitive function Psychological distress Quality of life Population-based longitudinal study 



This study was supported by the Danish Cancer Society.


  1. 1.
    EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRefGoogle Scholar
  2. 2.
    Nelson CJ, Nandy N, Roth AJ (2007) Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliat Support Care 5:273–280PubMedGoogle Scholar
  3. 3.
    Schagen SB, van Dam FS, Muller MJ et al (1999) Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640–650CrossRefPubMedGoogle Scholar
  4. 4.
    Wieneke MH, Dienst E (1995) Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 4:61–66CrossRefGoogle Scholar
  5. 5.
    Schagen SB, Muller MJ, Boogerd W et al (2006) Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 98:1742–1745PubMedCrossRefGoogle Scholar
  6. 6.
    Jenkins V, Shilling V, Deutsch G et al (2006) A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94:828–834CrossRefPubMedGoogle Scholar
  7. 7.
    Falleti MG, Sanfilippo A, Maruff P et al (2005) The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 59:60–70CrossRefPubMedGoogle Scholar
  8. 8.
    Shilling V, Jenkins V, Trapala IS (2006) The (mis)classification of chemo-fog—methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat 95:125–129CrossRefPubMedGoogle Scholar
  9. 9.
    Paganini-Hill A, Clark LJ (2000) Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 64:165–176CrossRefPubMedGoogle Scholar
  10. 10.
    Jenkins V, Shilling V, Fallowfield L et al (2004) Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13:61–66CrossRefPubMedGoogle Scholar
  11. 11.
    Palmer JL, Trotter T, Joy AA et al (2008) Cognitive effects of tamoxifen in pre-menopausal women with breast cancer compared to healthy controls. J Cancer Surviv Res Pract 2:275–282CrossRefGoogle Scholar
  12. 12.
    Debess J, Riis JØ, Pedersen L et al (2008) Cognitive function and quality of life after surgery for early breast cancer in North Jutland, Denmark. Acta Oncol 48:532–540CrossRefGoogle Scholar
  13. 13.
    ISPOC (2006) International study on postoperative cognitive dysfunction.
  14. 14.
    Schwarzer R, Jerusalem M (1995) Measures in health psychology: a user’s portfolio. Causal Control Beliefs 1:35–37Google Scholar
  15. 15.
    Luszczynska A, Gutiérrez-Doña B, Schwarzer R (2005) General self-efficacy in various domains of human functioning: evidence from five countries. Int J Psychol 40:80–89CrossRefGoogle Scholar
  16. 16.
    McNair DM, Heuchert JW (2003) Profile of mood states technical updates. Multi-Health Systems Inc, New YorkGoogle Scholar
  17. 17.
    Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376CrossRefPubMedGoogle Scholar
  18. 18.
    Fayers PM, Aaronson NK, Bjordal K et al (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer, BrusselsGoogle Scholar
  19. 19.
    Fayers P, Bottomley A (2002) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Eur J Cancer 38(Suppl 4):S125–S133CrossRefPubMedGoogle Scholar
  20. 20.
    Castaneda AE, Tuulio-Henriksson A, Marttunen M et al (2008) A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults. J Affect Disord 106:1–27CrossRefPubMedGoogle Scholar
  21. 21.
    Temkin NR, Heaton RK, Grant I et al (1999) Detecting significant change in neuropsychological test performance: a comparison of four models. J Int Neuropsychol Soc 5:357–369CrossRefPubMedGoogle Scholar
  22. 22.
    Resnick SM, Maki PM, Rapp SR et al (2006) Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab 91:1802–1810CrossRefPubMedGoogle Scholar
  23. 23.
    Hermelink K, Untch M, Lux MP et al (2007) Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 109:1905–1913CrossRefPubMedGoogle Scholar
  24. 24.
    Mehlsen M, Pedersen AD, Jensen AB et al (2009) No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psychooncology 18:248–257CrossRefPubMedGoogle Scholar
  25. 25.
    Wefel JS, Lenzi R, Theriault RL et al (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100:2292–2299CrossRefPubMedGoogle Scholar
  26. 26.
    Bender CM, Sereika SM, Berga SL et al (2006) Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 15:422–430CrossRefPubMedGoogle Scholar
  27. 27.
    Hurria A, Rosen C, Hudis C et al (2006) Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc 54:925–931CrossRefPubMedGoogle Scholar
  28. 28.
    Shilling V, Jenkins V (2007) Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 11:6–15CrossRefPubMedGoogle Scholar
  29. 29.
    Servaes P, Verhagen CA, Bleijenberg G (2002) Relations between fatigue, neuropsychological functioning, and physical activity after treatment for breast carcinoma: daily self-report and objective behavior. Cancer 95:2017–2026CrossRefPubMedGoogle Scholar
  30. 30.
    Dawson B, Trapp RG (2001) Basic & clinical biostatistics, 3rd edn. Lange Medical Books/McGraw-Hill Medical Publishing Division, New YorkGoogle Scholar
  31. 31.
    Collins B, Mackenzie J, Stewart A et al (2009) Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psychooncology 18:811–821CrossRefPubMedGoogle Scholar
  32. 32.
    Schilder CM, Eggens PC, Seynaeve C et al (2009) Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 48:76–85CrossRefPubMedGoogle Scholar
  33. 33.
    Moller JT, Cluitmans P, Rasmussen LS et al (1998) Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD investigators. International Study of Post-Operative Cognitive Dysfunction. Lancet 351:857–861CrossRefPubMedGoogle Scholar
  34. 34.
    Jansen CE, Miaskowski C, Dodd M et al (2005) A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 104:2222–2233CrossRefPubMedGoogle Scholar
  35. 35.
    Castellon SA, Ganz PA, Bower JE et al (2004) Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26:955–969CrossRefPubMedGoogle Scholar
  36. 36.
    Stewart A, Collins B, Mackenzie J et al (2008) The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology 17:122–130CrossRefPubMedGoogle Scholar
  37. 37.
    van Dam FS, Schagen SB, Muller MJ et al (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210–218CrossRefPubMedGoogle Scholar
  38. 38.
    Tannock IF, Ahles TA, Ganz PA et al (2004) Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 22:2233–2239CrossRefPubMedGoogle Scholar
  39. 39.
    Burgess C, Cornelius V, Love S et al (2005) Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 330:702. doi: 10.1136/bmj.38343.670868.D3 CrossRefPubMedGoogle Scholar
  40. 40.
    Mehnert A, Koch U (2007) Prevalence of acute and post-traumatic stress disorder and comorbid mental disorders in breast cancer patients during primary cancer care: a prospective study. Psychooncology 16:181–188CrossRefPubMedGoogle Scholar
  41. 41.
    Christensen S, Zachariae R, Jensen AB et al (2008) Prevalence and risk of depressive symptoms 3–4 months post-surgery in a nationwide cohort study of Danish women treated for early stage breast-cancer. Breast Cancer Res Treat 113:339–355CrossRefPubMedGoogle Scholar
  42. 42.
    Shapiro CL, Recht A (2001) Side effects of adjuvant treatment of breast cancer. N Engl J Med 344:1997–2008CrossRefPubMedGoogle Scholar
  43. 43.
    Browall M, Ahlberg K, Karlsson P et al (2008) Health-related quality of life during adjuvant treatment for breast cancer among postmenopausal women. Eur J Oncol Nurs 12:180–189CrossRefPubMedGoogle Scholar
  44. 44.
    Brandberg Y, Michelson H, Nilsson B et al (2003) Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401. J Clin Oncol 21:3659–3664CrossRefPubMedGoogle Scholar
  45. 45.
    Schou I, Ekeberg O, Ruland CM (2005) The mediating role of appraisal and coping in the relationship between optimism-pessimism and quality of life. Psychooncology 14:718–727CrossRefPubMedGoogle Scholar
  46. 46.
    Klee M, Groenvold M, Machin D (1997) Quality of life of Danish women: population-based norms of the EORTC QLQ-C30. Qual Life Res 6:27–34CrossRefPubMedGoogle Scholar
  47. 47.
    Ouimet LA, Stewart A, Collins B et al (2008) Measuring neuropsychological change following breast cancer treatment: an analysis of statistical models. J Clin Exp Neuropsychol 31(1):73–89CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Jeanne Debess
    • 1
    • 5
  • Jens Østergaard Riis
    • 2
  • Malene Cramer Engebjerg
    • 3
  • Marianne Ewertz
    • 4
  1. 1.Department of Oncology, Aalborg HospitalAarhus UniversityAalborgDenmark
  2. 2.Department of Neurology, Aalborg HospitalAarhus UniversityAalborgDenmark
  3. 3.Department of Clinical EpidemiologyAarhus University HospitalAarhus NDenmark
  4. 4.Department of Oncology, Odense University Hospital, Institute of Clinical ResearchUniversity of Southern DenmarkOdense CDenmark
  5. 5.University College of Northern DenmarkAalborg ØDenmark

Personalised recommendations